uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapykatie8288Jun 23, 20220 min read
Skyhawk Therapeutics Announces First U.S. Patients Dosed in Pivotal FALCON-HD Study Evaluating SKY-0515 in Huntington's Disease
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
Comments